NCI-2024-07865

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment (EmpowHER 303)

This Phase 3 study, called EmpowHER 303, is testing whether a new HER2-targeted drug called zanidatamab, combined with chemotherapy, works better and is as safe as the standard treatment trastuzumab with chemotherapy in people with metastatic HER2-positive breast cancer. The participants are patients whose cancer has spread and either stopped responding to or couldn’t tolerate a prior treatment called trastuzumab deruxtecan (Enhertu). The study is being conducted at multiple hospitals, and both doctors and patients know which treatment they’re receiving. The goal is to find out if zanidatamab can help control the cancer for longer or improve survival compared to current therapy.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

HER2-positive: It is a type of breast cancer where cancer cells have higher-than-normal levels of HER-2 receptors are called HER-2 positive. These receptors are like tiny doorways on the surface of the cells. HER-2 positive breast cancers tend to grow and spread faster than other kinds, but they also respond well to certain drugs that target the HER-2 receptor.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06435429

Clinical Trial Site: Sinai

To see all available clinical trials click here.